简短远程认知行为治疗对比注意控制对头颈癌幸存者体像困扰的疗效:一项先导随机临床试验
这项先导随机临床试验招募44例有体像困扰的头颈癌幸存者,分配至BRIGHT组(n=20)或注意控制组(n=24)。BRIGHT组在干预后1个月和3个月时IMAGE-HN评分改善均优于注意控制组,3个月时临床应答率更高(模型OR 6.6),效应量大(Cohen d=-0.9),且可接受性高。
要点
- BRIGHT组干预后3个月IMAGE-HN评分较注意控制组平均多降低17.1分(90%CI -25.6至-8.6)。
- 干预后3个月BRIGHT组临床应答率为注意控制组的6.6倍(模型OR 6.6;90%CI 2.0-21.8)。
- BRIGHT可接受性高,20例中19例(95%)可能或极可能向其他有体像困扰的头颈癌幸存者推荐。
核心结论
- 在这项先导随机临床试验中,BRIGHT可接受,可能带来头颈癌相关体像困扰的临床有意义改善,并显示高临床应答率。
- 这些有希望的初步数据支持开展大型疗效试验,以确立BRIGHT作为头颈癌幸存者体像困扰的首个循证治疗。
研究设计与样本
- 平行组先导随机临床试验,于2020年8月13日至2021年12月9日从南卡罗来纳医科大学头颈癌诊所常规幸存者随访中招募有体像困扰的成人头颈癌幸存者。
- 共44例头颈癌幸存者分配至BRIGHT组(n=20)或注意控制组(n=24);中位(范围)年龄63(41-80)岁,27例(61%)为女性。
- BRIGHT为5次每周由心理学家主导的视频远程认知行为治疗;注意控制为剂量和交付方式匹配的幸存者教育。
- 主要结局为IMAGE-HN评估的头颈癌相关体像困扰变化(评分范围0-84,分数越高表示体像困扰越重),临床应答率为IMAGE-HN评分达到临床有意义变化的患者比例。
- 数据分析时间为2022年5月3日至2022年6月16日。
主要发现
- BRIGHT组从基线至干预后1个月头颈癌相关体像困扰较注意控制组改善(IMAGE-HN评分变化模型均值差-7.9分;90%CI -15.9至0.0分)。
- BRIGHT组从基线至干预后3个月头颈癌相关体像困扰较注意控制组改善(IMAGE-HN评分变化模型均值差-17.1分;90%CI -25.6至-8.6分)。
- 干预后3个月BRIGHT组临床应答率较注意控制组高6.6倍(模型OR 6.6;90%CI 2.0-21.8)。
- 干预后3个月BRIGHT组较注意控制组头颈癌相关体像困扰改善具有临床意义,效应量大(Cohen d=-0.9;90%CI -1.4至-0.4)。
- 患者对BRIGHT可接受性评分高(所有指标平均评分≥4.5/5),20例接受BRIGHT的患者中19例(95%)可能或极可能向其他有体像困扰的头颈癌幸存者推荐。
关键数值与推荐
- IMAGE-HN评分范围0-84,分数越高表示头颈癌相关体像困扰越重。
- BRIGHT组干预后1个月IMAGE-HN评分变化模型均值差-7.9分(90%CI -15.9至0.0分),干预后3个月为-17.1分(90%CI -25.6至-8.6分),均相对注意控制组。
- 干预后3个月临床应答率模型OR为6.6(90%CI 2.0-21.8),BRIGHT组较注意控制组高6.6倍。
- 干预后3个月效应量Cohen d=-0.9(90%CI -1.4至-0.4),BRIGHT组较注意控制组。
- 可接受性所有指标平均评分≥4.5/5;20例中19例(95%)可能或极可能推荐BRIGHT。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although 1 in 4 head and neck cancer (HNC) survivors experience clinically significant body image distress (BID), a psychosocial morbidity that adversely affects quality of life, effective interventions for these patients are lacking. OBJECTIVE: To evaluate the acceptability and preliminary efficacy of BRIGHT (Building a Renewed ImaGe after Head and neck cancer Treatment), a brief tele-cognitive behavioral therapy, at reducing BID among HNC survivors. DESIGN, SETTING, AND PARTICIPANTS: This parallel-group pilot randomized clinical trial recruited adult HNC survivors with BID between August 13, 2020, and December 9, 2021, from the Medical University of South Carolina HNC clinic during a routine survivorship encounter. Data were analyzed from May 3 to June 16, 2022. INTERVENTIONS: BRIGHT consisted of 5 weekly psychologist-led video tele-cognitive behavioral therapy sessions. Attention control (AC) consisted of dose- and delivery-matched survivorship education. MAIN OUTCOMES AND MEASURES: Change in HNC-related BID was assessed using IMAGE-HN (Inventory to Measure and Assess imaGe disturbancE-Head and Neck), a validated patient-reported outcome (score range, 0-84, with higher scores indicating greater HNC-related BID). Clinical response rate was measured as the proportion of patients with a clinically meaningful change in IMAGE-HN scores. RESULTS: Of the 44 HNC survivors with BID allocated to BRIGHT (n = 20) or AC (n = 24), the median (range) age was 63 (41-80) years, and 27 patients (61%) were female. Patients rated BRIGHT's acceptability highly (all metrics had a mean rating of ≥4.5/5), and 19 of 20 patients (95%) receiving BRIGHT were likely or highly likely to recommend it to other HNC survivors with BID. BRIGHT decreased HNC-related BID from baseline to 1 month postintervention relative to AC (mean model-based difference in change in IMAGE-HN score, -7.9 points; 90% CI, -15.9 to 0.0 points) and from baseline to 3 months postintervention relative to AC (mean model-based difference in change in IMAGE-HN score, -17.1 points; 90% CI, -25.6 to -8.6 points). At 3 months postintervention, the clinical response rate of BRIGHT was 6.6-fold higher than AC (model-based odds ratio, 6.6; 90% CI, 2.0-21.8). The improvement in HNC-related BID for BRIGHT vs AC at 3 months was clinically significant, and the effect size was large (Cohen d, -0.9; 90% CI, -1.4 to -0.4). CONCLUSIONS AND RELEVANCE: In this pilot randomized clinical trial, BRIGHT was acceptable, may result in a clinically meaningful improvement in HNC-related BID, and showed a high clinical response rate. These promising preliminary data support conducting a large efficacy trial to establish BRIGHT as the first evidence-based treatment for HNC survivors with BID. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03831100.
引用
- Graboyes EM, Maurer S, Balliet W, et al. Efficacy of a Brief Tele-Cognitive Behavioral Treatment vs Attention Control for Head and Neck Cancer Survivors With Body Image Distress: A Pilot Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 36454561. doi:10.1001/jamaoto.2022.3700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。